Physician profile
Winter Dowland
NPI 1881905651
$3,670.19
in general payments reported to CMS, 2019-2025
15 companies · $3,073 in 2025
The $3,073 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $259 · 2022: $53.87 · 2023: $20.89 · 2025: $3,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $93.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $93.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,044.36 | 2025 | |
| Minerva Surgical, INC | $259.19 | 2019-2020 | |
| Abbvie INC. | $129.78 | 2020 | |
| Duchesnay USA Incorporated | $49.74 | 2019 | |
| Organon LLC | $39.59 | 2022 | |
| Sumitomo Pharma America, INC. | $28.58 | 2025 | Myfembree |
| Gynesonics, INC. | $20.89 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Allergan, INC. | $19.46 | 2019 | |
| Exeltis, USA INC. | $14.49 | 2019 | |
| Boston Scientific Corporation | $14.28 | 2022 | |
| Avion Pharmaceuticals | $13.65 | 2020 | |
| Therapeuticsmd, INC. | $13.58 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.07 | 2019 | |
| Aspira Women'S Health INC | $10.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winter Dowland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.